HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Candida infective endocarditis: an observational cohort study with a focus on therapy.

Abstract
Candida infective endocarditis is a rare disease with a high mortality rate. Our understanding of this infection is derived from case series, case reports, and small prospective cohorts. The purpose of this study was to evaluate the clinical features and use of different antifungal treatment regimens for Candida infective endocarditis. This prospective cohort study was based on 70 cases of Candida infective endocarditis from the International Collaboration on Endocarditis (ICE)-Prospective Cohort Study and ICE-Plus databases collected between 2000 and 2010. The majority of infections were acquired nosocomially (67%). Congestive heart failure (24%), prosthetic heart valve (46%), and previous infective endocarditis (26%) were common comorbidities. Overall mortality was high, with 36% mortality in the hospital and 59% at 1 year. On univariate analysis, older age, heart failure at baseline, persistent candidemia, nosocomial acquisition, heart failure as a complication, and intracardiac abscess were associated with higher mortality. Mortality was not affected by use of surgical therapy or choice of antifungal agent. A subgroup analysis was performed on 33 patients for whom specific antifungal therapy information was available. In this subgroup, 11 patients received amphotericin B-based therapy and 14 received echinocandin-based therapy. Despite a higher percentage of older patients and nosocomial infection in the echinocandin group, mortality rates were similar between the two groups. In conclusion, Candida infective endocarditis is associated with a high mortality rate that was not impacted by choice of antifungal therapy or by adjunctive surgical intervention. Additionally, echinocandin therapy was as effective as amphotericin B-based therapy in the small subgroup analysis.
AuthorsChristopher J Arnold, Melissa Johnson, Arnold S Bayer, Suzanne Bradley, Efthymia Giannitsioti, José M Miró, Pilar Tornos, Pierre Tattevin, Jacob Strahilevitz, Denis Spelman, Eugene Athan, Francisco Nacinovich, Claudio Q Fortes, Cristiane Lamas, Bruno Barsic, Nuria Fernández-Hidalgo, Patricia Muñoz, Vivian H Chu
JournalAntimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 59 Issue 4 Pg. 2365-73 (Apr 2015) ISSN: 1098-6596 [Electronic] United States
PMID25645855 (Publication Type: Journal Article, Observational Study, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2015, American Society for Microbiology. All Rights Reserved.
Chemical References
  • Antifungal Agents
  • Echinocandins
  • Amphotericin B
Topics
  • Adult
  • Age Factors
  • Aged
  • Amphotericin B (therapeutic use)
  • Antifungal Agents (administration & dosage, therapeutic use)
  • Candidiasis (drug therapy, microbiology, mortality)
  • Cohort Studies
  • Cross Infection (drug therapy, mortality)
  • Echinocandins (therapeutic use)
  • Endocarditis (drug therapy, microbiology, mortality)
  • Female
  • Hospital Mortality
  • Humans
  • Male
  • Middle Aged
  • Prospective Studies
  • Risk Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: